Home » Newsletters » BioWorld Science

BioWorld Science

June 2, 2015

View Archived Issues

Santen Pharmaceutical discloses preclinical and clinical data for DE-117

Investigators report phase I results for NS-065/NCNP-01

rSIV.F/HN-hCEF-sohAAT gives therapeutic expression of AAT for inflammatory lung diseases

Merck & Co. and NanoString to identify gene expression biomarkers for Keytruda response

Padlock Therapeutics licenses protein-arginine deiminase assets from GSK

Medifocus obtains option to license cancer immunotherapy technology from Duke University

Researchers describe the functional loss of HSD17B3 mutant G133R

IL-15/sIL-15Ra gene therapy active in multi-organ tumor model

Purdue Pharma patents Nav1.7 channel blockers

Allergan presents S1P1 receptor modulators

ASCO news: First-in-human data for JW Pharmaceutical's CWP-232291 in AML and MDS

Phase II study investigates JM-010 for levodopa-induced dyskinesia

Fudan University discloses IDO inhibitors

University of Malaya and Aurigene Discovery Technologies report new FabL inhibitors

Lilly and AstraZeneca enter clinical trial collaboration to study MEDI-4736 with ramucirumab

Phase I/II safety and efficacy results for treatment of EGFR mutation-positive NSCLC

Merck Serono signs collaboration agreement with Genea Biomedx for fertility technologies

Halozyme and Ventana collaborate on PEGPH-20 companion diagnostic assay

Chengdu Easton Pharmaceutical divulges FXa inhibitors

Cannabis Science and IGXBio to investigate combination of CS-TATI-1 and GenePro in HIV

FDA approves Rapamune for lymphangioleiomyomatosis

Amgen and Merck & Co. expand immunotherapy collaboration

FDA accepts for review sBLA for Keytruda in advanced NSCLC

European approval for Lenvima in radioactive iodine-refractory differentiated thyroid carcinoma

FDA accepts BLA for anthrax toxin antibody Anthim

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
Deals and an M&A strengthen end-of-year numbers
BioWorld
Two large deals and an acquisition, totaling about $4.64 billion in all, are helping wrap up what’s turning out to be a strong year. Through the first 11 months...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...
Neutrophils put the brakes on fat loss
BioWorld Science
Fat tissue balances energy by storing lipids during times of abundance and mobilizing them when needed, yet sustained metabolic stress demands mechanisms that...